Multispecific deimmunized CD3-binders

US9102736B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Robert Hofmeister · Scituate, US
• Birgit Kohleisen · Munich, DE
• Ulla Lenkkeri-Schütz · Unterschleißheim, DE
• Christian Itin · Menlo Park, US
• Patrick Bauerle · Gauting, DE
• Francis Joseph Carr · Aberdeen, GB
• Anita Hamilton · Aberdeen, GB
• Stephen Williams · Laramie, US

Key dates

• Filing date: Dec 12, 2011
• Grant date: Aug 11, 2015
• Expiry date: Mar 11, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/567
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.